- Home
- Publications
- Publication Search
- Publication Details
Title
Modulatory effects of bortezomib on host immune cell functions
Authors
Keywords
-
Journal
Immunotherapy
Volume 7, Issue 9, Pages 1011-1022
Publisher
Future Medicine Ltd
Online
2015-09-01
DOI
10.2217/imt.15.66
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells
- (2013) Xiangling Wang et al. ANTI-CANCER DRUGS
- Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1
- (2013) Matthieu Cornelis Johannes Bosman et al. EXPERIMENTAL HEMATOLOGY
- Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells
- (2013) Jee-Eun Kim et al. PHARMACOLOGICAL RESEARCH
- Proteasome Inhibition Profoundly Affects Activated Human B Cells
- (2013) Arend Mulder et al. TRANSPLANTATION
- Attenuation of Early Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice by Proteasome Inhibition
- (2012) Nicola Wilck et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells
- (2012) Xin Mao et al. INFLAMMATION
- Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis
- (2012) Wei Liu et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells
- (2012) Konstantinos Tsapakidis et al. INTERNATIONAL JOURNAL OF UROLOGY
- Immune Mechanism of the Antitumor Effects Generated by Bortezomib
- (2012) C.-L. Chang et al. JOURNAL OF IMMUNOLOGY
- Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands
- (2012) Laura Jardine et al. LEUKEMIA & LYMPHOMA
- Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
- (2012) Ali R. Jazirehi et al. MOLECULAR CANCER THERAPEUTICS
- Ischemia–reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation
- (2012) Sabarinathan Ramachandran et al. TRANSPLANT IMMUNOLOGY
- Acquired STAT4 deficiency as a consequence of cancer chemotherapy
- (2011) I. P. Lupov et al. BLOOD
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation
- (2011) D Xu et al. LEUKEMIA
- Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens
- (2011) Belén Blanco et al. LEUKEMIA RESEARCH
- Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma
- (2011) Feng Chen et al. CELLULAR ONCOLOGY
- The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
- (2010) J. M. Seeger et al. CANCER RESEARCH
- Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib
- (2010) Ulrike Heider et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
- (2010) N. Schmidt et al. GUT
- Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection
- (2010) Seiko Iwata et al. INTERNATIONAL JOURNAL OF CANCER
- The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells
- (2010) Xiaoli Feng et al. MOLECULAR IMMUNOLOGY
- Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation
- (2010) Ashenafi Y Tilahun et al. MOLECULAR THERAPY
- Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy
- (2010) James J. Driscoll et al. Targeted Oncology
- Structure, Assembly and Homeostatic Regulation of the 26S Proteasome
- (2010) Y. Xie Journal of Molecular Cell Biology
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition
- (2009) E. Ames et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
- (2009) Maria Berg et al. CYTOTHERAPY
- Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
- (2009) B. Blanco et al. HAEMATOLOGICA
- Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo
- (2009) Elisabeth Zinser et al. IMMUNOBIOLOGY
- Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells
- (2009) A. Lundqvist et al. JOURNAL OF IMMUNOLOGY
- Proteasome Regulation of ULBP1 Transcription
- (2009) James E. Butler et al. JOURNAL OF IMMUNOLOGY
- Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
- (2009) Tianhong Li et al. LUNG CANCER
- Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
- (2008) A. S. M. Yong et al. BLOOD
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
- (2008) S. Armeanu et al. CLINICAL CANCER RESEARCH
- Dampening Ab responses using proteasome inhibitors followingin vivo B cell activation
- (2008) Paolo Cascio et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Proteasome inhibition suppresses essential immune functions of human CD4+T cells
- (2008) Carsten Berges et al. IMMUNOLOGY
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
- (2008) A. Shanker et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More